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down-regulating the expressions of IL-10 and TGF-b, anti-
inﬂammatory cytokine, and promoting the IL-12 expression,
pro-inﬂammatory cytokine. With HBV subunit vaccine, CIM
can also enhance antigen speciﬁc cell-mediated response in
animals.
The combination of LMS and CIM can synergistically enhance
the immunogenicity of HBV subunit vaccine and leads to a
robust at a comparative level achieved with CpG+alum in
animals. Since the safety proﬁle of the two chemicals, their
combination with the HBV subunit vaccine may provide a
cost effective and safe, yet effective therapy to treat those
individuals chronically infected by HBV.
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I-64 Viral factors of hepatocellular carcinoma in chronic
hepatitis B
H.L.Y. Chan*. The Chinese University of Hong Kong, China
Chronic hepatitis B is the commonest cause of
hepatocellular carcinoma (HCC) in Asia. Various clinical
factors including older age, male gender, positive HBeAg
and liver cirrhosis have been suggested to associate with
a higher risk of HCC. Higher HBVDNA has been shown by
various longitudinal studies to associate with a higher risk of
liver cirrhosis and HCC. We have performed a longitudinal
study comparing the serial HBVDNA among patients who
developed and did not develop HCC. The trough HBVDNA
level seemed to be the most important determinant of HCC
development.
We have performed a prospective longitudinal study among
426 chronic hepatitis B patients with a follow-up up to
5 years. Genotype C HBV is found to be an independent risk
factor of HCC over genotype B HBV. This is probably related
to the more active liver disease and higher proportion of
basal core promoter mutations related to genotype C HBV.
In another study including 1006 patients followed up for
over 7 years, HBV subgenotype Ce was found to associate
with highest risk of HCC independent of HBVDNA levels.
To further investigate the virological mechanism of HCC by
different HBV genotypes/subgenotypes, we have performed
full genome sequencing of the HBV in 100 chronic hepatitis B
patients with HCC and another 100 patients without
HCC. Different viral genotypes and subgenotypes have
different viral genomic markers for HCC. After data mining,
algorithms can be derived with a sensitivity of HCC
prediction of 70% 80%.
I-65 Hepatitis B and C viral cellular interactions in the
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On a global scale, chronic hepatitis B virus (HBV) and
hepatitis C virus (HCV) account for well over 90% of
hepatocellular carcinoma (HCC). Our Liver Research Center
has been interested in viral-cellular protein interactions
that may be responsible for this exceedingly high risk of
hepatocyte transformation during persistent viral infection
and how anti-viral agents may reduce this risk. There
are two major signal transduction pathways that appear
to be activated in most HCC and may occur very early
in the disease process such as in dysplastic hepatocytes.
The ﬁrst is the insulin/IGF-1/IRS-1 signal transduction
pathway involved in hepatocyte growth and survival. The
other major signaling pathway involves the Wnt/Frizzled/b-
catenin cascade involved in cell migration and proliferation
normally “on” during embryonic development. However,
aberrant activation of this pathway in adults can lead to
tumor formation through its stimulatory effects on cell
migration, invasion, and cell proliferation.
Finally, we will discuss recent reports that demonstrate
interactions of HCV and HBV structural and non-structural
proteins on various components of these two pathways that
tend to promote activation during chronic viral infection.
A further understanding of the interaction of viral and
hepatocyte-derived cellular proteins will provide insights
into the molecular mechanisms of HBV and HCV related HCC
and begin to deﬁne the critical role of these interactions in
the transformation process. These studies describe essential
molecular mechanisms that may serve as targets for
possible therapeutic intervention in addition to approaches
that reduce viral replication and persistence via anti-viral
agents.
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Hepatocellular carcinoma (HCC) is one of the major
malignant diseases in Asia. The incidence rates of HCC
geographically differ according to high prevalence of
hepatitis B virus (HBV) infection.
Chronic necro-inﬂammation by persistent HBV infection can
progress to cirrhosis and meanwhile genetic changes can
lead to the occurrence of HCC. Long standing inﬂammatory
activities may play an important role in the clinical course
of HBV infection. We studied 188 patients with chronic
hepatitis B for a mean of 80.6 months to evaluate the long-
term outcome of chronic hepatitis B patients, based on the
histological grade and stage, in Korea. The development of
cirrhosis correlated well with the grade of porto-periportal
activity and stage of ﬁbrosis (p < 0.05). Patients with a higher
grade of porto-periportal activity and higher stage of ﬁbrosis
had a greater chance of developing cirrhosis. Based on ALT
levels during follow-up, we classiﬁed the patients into active
and inactive biochemical hepatitis groups. The probabilities
of developing cirrhosis, decompensation, and HCC were
signiﬁcantly higher in the active biochemical hepatitis group
(p < 0.01). Multivariate analysis showed that the prognostic
factors for developing cirrhosis and decompensation were
age and biochemical hepatitis activity during follow-up.
From our follow-up study, we can conclude that
development of cirrhosis correlated well with the grade
of porto-periportal activity and stage of ﬁbrosis at liver
biopsy. In addition, biochemical hepatitis activity during the
follow-up was an independent prognostic factor affecting
the long-term outcome of chronic hepatitis B. Therefore,
effective control of hepatitis activity might improve the
long-term outcome of chronic hepatitis B patients.
In high endemic areas of chronic HBV infection, a screening
program to detect HCC development conﬁned to the
patients with chronic B viral liver disease is necessitated.
The cost-effectiveness of a screening program could
probably be increased further by focusing the screening
of patients according to the risk factors most likely to
affect them. Therefore, it is very important to assess the
risk factors of HCC development. We demonstrated that
the more risk factors, the higher HCC development. A
tailored screening system with individual prediction model
for HCC was also proposed based on relative signiﬁcance
of risk factors and prospectively conﬁrmed. Recent our
study of 688 patients with chronic B viral liver diseases
